For UK healthcare professionals only
Media partner:
GPnotebook
This website includes promotional information and is intended for UK healthcare professionals only. This website has been funded by Exeltis UK. Prescribing information and adverse event reporting information can be found at the bottom of the page. The media partner for this activity is GPnotebook. GPnotebook has had no input into the content of this website.

Welcome to the Exeltis Women’s Health Hub

Supporting better care with evidence-based resources

The Exeltis Women’s Health Hub is a comprehensive resource designed to support healthcare professionals in managing key areas of women’s health.

Our content focuses on evidence-based approaches to contraception, the clinical assessment and treatment of menopausal symptoms, helping your patient through the transition from peri-menopause to post-menopause, and the management of nausea and vomiting in pregnancy (NVP).

Contraception
Discover more about SLYND® (drospirenone) – a progestogen-only pill (POP) indicated for contraception. The first oestrogen-free drospirenone POP in the UK1,2

Explore contraception ›

Menopause

Explore FEMOSTON® (estradiol/dydrogesterone) – a combined oral HRT for the relief of oestrogen deficiency symptoms, covering a wide range of doses from sequential to continuous preparations3-6

Explore menopause ›

Pregnancy

Learn more about XONVEA® (doxylamine succinate/pyridoxine hydrochloride) – the only licensed treatment in the UK specifically for NVP7

Explore pregnancy ›

Resource highlights

Explore our resources to stay current, confident and informed in the evolving field of women’s health

45:23

ON-DEMAND

Managing bleeding issues with hormonal contraception

Dr Diana Mansour

Consultant in Community Gynaecology, Newcastle upon Tyne, UK

58:32

ON-DEMAND

Navigating oral HRT in modern menopause management

Dr Vikram Talaulikar

BMS-accredited Menopause Specialist and Honorary Associate Professor in Women’s Health, University College London

33:27

ON-DEMAND

Nausea and vomiting in pregnancy: What can be done to improve patient outcomes?

Dr Melanie Nana

NIHR Clinical Research Fellow, King’s College London

Visit the Exeltis Hub to register for upcoming webinars and access on-demand videos and clinical tools

Discover more

Sign up to hear from Exeltis

All fields required

I consent to receive news and information about Exeltis UK’s brands and products. I understand my personal data becomes processed according the Exeltis UK privacy notice. View Privacy Policy I understand I can withdraw consent whensoever.
You can unsubscribe at any time by clicking the unsubscribe link in the footer of our emails.

HRT, hormone replacement therapy; NVP, nausea and vomiting in pregnancy.

References

  1. SLYND® (drospirenone). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15275/smpc#gref (Accessed September 2025).
  2. FSRH Clinical Guidelines progestogen-only pills. 11/2022.
  3. FEMOSTON® 1 mg/10 mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/5523/smpc#gref (Accessed September 2025).
  4. FEMOSTON® 2 mg/10 mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3903/smpc#gref (Accessed September 2025).
  5. FEMOSTON®-conti 0.5 mg/2.5 mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2825/smpc#gref (Accessed September 2025).
  6. FEMOSTON®-conti 1 mg/5 mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/1347/smpc#gref (Accessed September 2025).
  7. XONVEA® (doxylamine succinate/pyridoxine hydrochloride). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/14892/smpc (Accessed September 2025).

Prescribing and adverse event reporting information:

FEMOSTON® (estradiol/dydrogesterone)

SLYND® (drospirenone)

XONVEA® (doxylamine succinate/pyridoxine hydrochloride)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Exeltis UK Limited by email to [email protected]

EXE-E/INP-CORP-1872-v1 | September 2025

For UK healthcare professionals only
GPnotebook

This website includes promotional information and is intended for UK healthcare professionals only. This website has been funded by Exeltis UK

This site is intended for UK healthcare professionals only

To continue, please confirm that you are a UK healthcare professional by selecting one of the buttons below.

Yes, I am a UK healthcare professional
No, I am not a UK healthcare professional

You are leaving https://resources.gpnotebook.com

Text

Text

Close

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel